Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: Need of comparative clinical trials in resistant patients

被引：2

作者：

D'Incalci, M ^{[1
]}

机构：

[1] Ist Ric Farmacol Mario Negri, Dept Oncol, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 1997年 / 8卷 / 12期

关键词：

D O I：

10.1023/A:1008262515174

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1183 / 1184

页数：2

共 4 条

[1] DOCETAXEL - CURRENT STATUS AND FUTURE-PROSPECTS [J].

EISENHAUER, EA .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (12) :2865-2868

[2] PHASE-II TRIAL OF DOCETAXEL IN ADVANCED ANTHRACYCLINE-RESISTANT OR ANTHRACENEDIONE-RESISTANT BREAST-CANCER [J].

RAVDIN, PM ;

BURRIS, HA ;

COOK, G ;

EISENBERG, P ;

KANE, M ;

BIERMAN, WA ;

MORTIMER, J ;

GENEVOIS, E ;

BELLET, RE .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (12) :2879-2885

[3] PHASE-II TRIAL OF DOCETAXEL - A NEW, HIGHLY EFFECTIVE ANTINEOPLASTIC AGENT IN THE MANAGEMENT OF PATIENTS WITH ANTHRACYCLINE-RESISTANT METASTATIC BREAST-CANCER [J].

VALERO, V ;

HOLMES, FA ;

WALTERS, RS ;

THERIAULT, RL ;

ESPARZA, L ;

FRASCHINI, G ;

FONSECA, GA ;

BELLET, RE ;

BUZDAR, AU ;

HORTOBAGYI, GN .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (12) :2886-2894

[4] Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) [J].

Vanhoefer, U ;

Cao, S ;

Harstrick, A ;

Seeber, S ;

Rustum, YM .

ANNALS OF ONCOLOGY, 1997, 8 (12) :1221-1228

← 1 →